W. van Weelden

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.

C. Moiola, K. K. van de Vijver, F. Amant, 2021, Gynecologic oncology.

EP645 Anti-estrogen treatment in endometrial cancer: a systematic review

A. Romano, L. Massuger, J. Pijnenborg, 2019, International Journal of Gynecological Cancer.